Labcorp Expands Global Clinical Trial Footprint with MLM Medical Labs Acquisition
Event summary
- Labcorp acquires MLM Medical Labs, expanding its central laboratory network to four continents: North America, Europe, Asia, and Africa.
- MLM brings specialized laboratory operations in the U.S., Germany, and South Africa, including Africa’s first fully CAP-accredited central lab.
- The deal strengthens Labcorp’s biomarker and specialty testing capabilities for complex clinical development programs.
- Financial terms of the transaction were not disclosed.
The big picture
Labcorp’s acquisition of MLM Medical Labs solidifies its dominance in the clinical trial services sector, addressing the growing demand for global reach and specialized testing capabilities. The move comes as biopharma companies increasingly rely on outsourced central labs to manage complex, multinational trials. With this deal, Labcorp positions itself as a one-stop partner for sponsors, from emerging biotechs to major pharmaceutical firms, reinforcing its role in advancing drug development worldwide.
What we're watching
- Integration Challenges
- How Labcorp will merge MLM’s science-led service model with its existing global infrastructure.
- Market Positioning
- Whether Labcorp can sustain its lead as the only central lab provider with a wholly owned network across four continents.
- Regulatory Compliance
- The pace at which Labcorp can ensure consistent regulatory oversight across its expanded global footprint.
Related topics